AstraZeneca (AZN) launched FluMist Home, the at-home delivery service for Flumist. Flumist is the first and only seasonal influenza vaccine approved to be self-administered by adults 18 to 49 years of age or administered by a parent or caregiver to individuals 2-17 years of age.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- Soros boosts exits stake in AstraZeneca, cuts position in Alphabet
- AstraZeneca’s iCaReMe Global Registry: A Real-World Study on Chronic Disease Management
- AstraZeneca’s New Study on CRT Patterns in Russia: A Potential Game-Changer for Lung Cancer Treatment
- AstraZeneca’s CKD Registry Study: A Strategic Move in Nephrology
- AstraZeneca’s Real-World Study on Tezepelumab: A Potential Game-Changer for Severe Asthma